39 citations,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
37 citations,
May 2016 in “Deutsches Arzteblatt International” Hair loss requires customized treatments based on its various causes and types.
26 citations,
June 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Regenerative therapies show promise for treating vitiligo and alopecia areata.
25 citations,
October 2019 in “JAAD Case Reports” Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
24 citations,
October 2018 in “JAAD Case Reports” A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
23 citations,
October 2020 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” Tailored treatments for alopecia areata are recommended based on severity and patient needs.
23 citations,
October 2018 in “Expert Opinion on Drug Safety” Consider benefits and risks of new alopecia treatments for safety.
20 citations,
January 2017 in “Actas Dermo-Sifiliográficas” Recent advances in hair loss treatments show significant progress.
13 citations,
February 2019 in “Journal of the American Academy of Dermatology” The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.
9 citations,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
8 citations,
January 2017 in “Dermatology online journal” Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
7 citations,
April 2021 in “British Journal of Dermatology” Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.
5 citations,
January 2022 in “Dermatology Reports” Tofacitinib treatment for hair loss may worsen acne.
4 citations,
July 2018 in “PubMed” Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.
2 citations,
November 2021 in “ACG Case Reports Journal” Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
2 citations,
April 2019 in “Dermatologic Therapy” A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
2 citations,
March 2015 in “Expert opinion on orphan drugs” New treatments for hair loss show promise but need more research to confirm safety and effectiveness.
2 citations,
November 2014 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.
2 citations,
May 2020 in “JAAD case reports” Ruxolitinib can cause a delayed skin reaction on the nose.
2 citations,
June 2018 in “Journal of the American Academy of Dermatology” Alopecia areata causes varying hair loss and nail changes, and treatments include topical, systemic, and injectable therapies.
1 citations,
October 2023 in “Dermatology and therapy” Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
1 citations,
January 2023 in “Przegląd Dermatologiczny” The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
1 citations,
October 2018 in “InTech eBooks” Only minoxidil and finasteride are FDA-approved for hair loss, with other treatments available but less effective or with side effects.
1 citations,
May 2017 in “InTech eBooks” The document concludes that alopecia areata is an unpredictable autoimmune hair loss condition with no cure, but various treatments exist that require personalized approaches.
1 citations,
July 2019 in “Medicina Clínica (English Edition)” Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
1 citations,
April 2018 in “Journal of Investigative Dermatology” Fzd2 is important for skin and hair development through various signaling ways.
November 2023 in “Aktualʹnì problemi sučasnoï medicini” The guidelines suggest using various treatments, including antidepressants and steroids, for alopecia areata and discuss the condition's genetic and immune aspects.
April 2024 in “Journal of clinical medicine” Effective treatment guidelines for frontal fibrosing alopecia are still unclear.
September 2023 in “Dermatology and Therapy” Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.
August 2023 in “Journal of The American Academy of Dermatology” Early treatment is key for permanent hair loss disorders, with options ranging from medications and phototherapy to immunomodulators and antibiotics, depending on severity and type.